

Subject Index

4 π microscopy 48, 58, 59

A

Abbe principle 46, 48
 activation-induced cell death (AICD) 97, 101, 102, 107, 108, 112, 193
 AFM, *see* atomic force microscopy
 AICD, *see* activation-induced cell death
 anchored-protein picket model 125, 131–134, 137–140, 146
 anti-Tac (anti-CD25, anti-IL-2Ralpha) monoclonal antibody 77, 89, 98, 111
 apoptosis 7
 – coupled with TNFR signaling 171, 173, 176, 177–179, 180, 182, 186, 187, 191, 192, 195, 196, 197
 – of T cells 3, 6, 17, 18, 107, 108, 113, 293, 304–307
 – role of ion channels 304–307
 association patterns of membrane proteins, *see also* protein clusters 14–18, 42, 55, 56–58, 60, 61, 71–90
 atomic force microscopy (AFM) 80, 90, 132

B

B cells 3, 7, 78, 79, 80, 81, 97, 98, 100, 101, 102, 105, 112, 173, 182, 185, 188, 189, 190, 191, 195, 197, 198, 217, 231, 232, 239, 240, 241, 243, 244, 302
 basophils 212, 243, 244, 245, 265, 271, 279
 bioluminescence resonance energy transfer (BRET) 156–157

C

cADPr, *see* cyclic ADP-ribose
 calcium (Ca²⁺) channels
 – Ca²⁺ release-activated Ca²⁺ (CRAC) channels 294, 295, 296–297, 298, 300, 306
 – CRAC channels, *see* Ca²⁺ release-activated Ca²⁺ channels
 – L-type 266, 272
 – N-type 276
 CARD, *see* caspase activation and recruitment domain
 caspase activation and recruitment domain (CARD) 177, 179

caspases 41, 42, 108, 173, 175, 178, 179, 180, 186, 189, 191, 305, 307
 chemokine receptors 153–165
 – homo- and heterodimerization 155–161, 162, 164, 165
 chemokines 112, 153–165, 194, 212, 222, 223, 280
 – G protein activation 154, 155, 161, 162
 – JAK/STAT activation 155, 161, 162
 chloride (Cl⁻) channels
 – in apoptosis 306
 – in volume regulation 303, 304
 Cl⁻ channels, *see* chloride channels
 CLSM, *see* confocal microscopy
 common gamma chain (γ_c)
 – of cytokine receptors 8, 10, 11, 79, 81, 97–113
 compartmentalized fluid model 123, 124, 125, 126, 127, 140
 confocal (laser scanning) microscopy (CLSM) 47, 48, 57, 60, 62, 80, 82, 83, 85, 88, 105, 155
 cyclic ADP-ribose (cADPr) 294, 295, 296
 cytokines, *see also* IL-2, IL-15, chemokines and TNF 1, 3, 7–12, 14, 16, 17, 19, 81, 82, 97–113, 153–165, 171–198, 212, 214, 215, 216, 217, 219, 220, 221, 222, 223, 224, 225, 228, 230, 234, 235, 242, 245, 246, 265, 273, 280

D

DD, *see* death domain
 death domain (DD) 171, 173, 176, 177, 178, 180, 181, 186, 189, 191, 192, 194, 196, 305
 death-inducing signaling complexes (DISC) 175, 178, 179, 186
 decoy receptors 171, 172, 173, 175, 176, 191, 192, 194, 195, 196, 197
 DISC, *see* death-inducing signaling complexes
 DOPE, dioleoylphosphatidylethanolamine 131–138, 145

E

ectodysplasin (EDA) 175, 192–193
 – receptor of (EDAR) 173, 192–193
 EDA, *see* ectodysplasin
 electron microscopy 43, 44, 80, 90, 302
 eosinophils 212, 243, 278, 279, 280, 281

- epithelial cells 131, 223
 – in T cell function 1, 9–12, 18, 19
- ErbB proteins
 – homo- and heteroassociations of 56, 57, 60, 61
 – internalization of 60, 61, 62
 – large-scale associations of 57, 58
 – tyrosine phosphorylation of 60, 61, erythrocytes, *see* red blood cells
- F**
- Fas (Apo-1, CD95) 107, 108, 171, 173, 175, 178, 180, 186, 191, 193, 305, 306, 307
- FcεRI signaling 211–246
 – adaptors in 213, 216, 217, 219, 220, 222, 227, 228, 233–234, 236–237, 243, 246
 – protein tyrosine kinases (PTK) in 211, 212, 213, 215, 216–224, 227, 228, 229, 230, 231, 232, 233, 234, 235, 237, 246
 – protein tyrosine phosphatases (PTP) in 216, 227, 229–232, 243, 245
 – PTKs in, *see* protein tyrosine kinase
 – PTPs in, *see* protein tyrosine phosphatase
- FcεRI, *see* type I Fcε receptor
- FcεRI-induced secretory response 211–246
 – cytokines 212, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 225, 227, 228, 230, 233, 234, 239, 242, 243, 246
 – degranulation, *see* granule-stored mediators
 – de novo synthesized mediators 212, 214, 217, 219, 222, 223, 224, 228, 233, 240, 246
 – granule-stored (preformed) mediators 212, 214, 216, 217, 219, 220, 221, 222, 223, 226, 228, 229, 230, 233, 234, 235, 236, 237, 239, 240, 241, 242, 243, 244
- FLAsH (fluorescein arsenical helix-binder ethanedithiol) 43–44
- fluid mosaic membrane model, Singer-Nicolson, *see also* two-dimensional continuum fluid model 71, 126, 137
- fluorescence complementation
 – bimolecular (BiFC) 42
 – multicolor 42
- fluorescence correlation spectroscopy (FCS) 82–90
 – autocorrelation function 83–89
 – cross-correlation function 85–89
 – diffusion time 85, 86, 88, 89
 – fluctuation microscope for 87
 – fluorescence cross-correlation spectroscopy (FCCS) 73, 85, 88, 105
 – sensitivity of 83, 85
- fluorescence microscopy 33–62
 – spatial resolution of 33, 34
- fluorescence redistribution after photobleaching (FRAP) 123, 127, 128, 129, 130, 133, 134, 135, 137
- fluorescence resonance energy transfer (FRET) 33, 37, 41, 42, 49–51, 60, 73, 74–77, 104, 105, 156–157, 158, 301
 – acceptor photobleaching 52, 54, 57, 60, 83, 88, 156, 158
 – combined detection of donor and acceptor fluorescence 54
 – donor fluorophore lifetime (FLIM) 52, 156, 158, 159
 – donor photobleaching 53, 57
 – donor quenching 51, 52
 – flow cytometry (FCET) 52, 54, 57, 73, 74–77, 79, 80, 82, 88
 – FRET sensitized photobleaching of acceptor 53, 54
 – homo-FRET 41, 42, 55, 56
 – mapping the distribution of membrane proteins with 78–82, 83, 90
 – microscopy (pixel-by-pixel) 52, 54, 57, 60, 73, 74, 83, 88
 – photochromic (pcFRET) 52, 53, 54
 – sensitized acceptor fluorescence 52, 156, 157
 – single-molecule FRET 140–148
- fluorescent labeling 33, 35–46
 – steric effect of 45
 – with (monoclonal) antibodies 35, 45, 52, 56, 57, 58, 59, 60, 61, 75, 76, 77, 83, 85, 89, 156
 – with avidin 35
 – with biarsenical derivatives of fluorophores 42–43
 – with Fab fragments 35, 45, 56, 60, 62, 75, 78
 – with quantum dots 43–45
 – with visible fluorescent proteins (VFPs) 36–42
- FRET, *see* fluorescence resonance energy transfer
- FRAP, *see* fluorescence redistribution after photobleaching
- G**
- GFP, *see* green fluorescent protein
- GPCR, *see* G-protein coupled receptors
- G-protein coupled receptors (GPCR) 129, 153, 154, 155, 158, 160, 161, 162, 223, 265, 266, 274, 276, 278,
- green fluorescent protein (GFP), *see also* visible fluorescent proteins (VFP) 34, 36, 37, 41, 42, 55, 56, 58, 59, 138, 145, 146, 148, 156
 – photoactivation of 40–41
- H**
- histamine 220, 230, 232, 243, 265–282
 – in allergy 265, 270, 273, 281,
 – in chemotaxis 271, 280, 281,
 – FcεRI-mediated release of 220, 230, 232, 243
 – in inflammation 265, 270, 279, 280, 281
 – R-α-methylhistamine 275, 276, 277, 278

- histamine receptors 265–282
- H₁ receptor (H₁R) 265, 266–270, 271, 272, 273–274, 278, 279, 281, 282
 - H₂ receptor (H₂R) 265, 269, 271–274, 278, 279, 280, 282
 - H₃ receptor (H₃R) 274–278, 279, 282
 - H₄ receptor (H₄R) 275, 278–282
 - in neoplasias 265, 273–274
 - in the central nervous system 265, 270, 274–277
 - in the gastrointestinal system 268, 270, 271, 272, 273,
 - in the immune system 270, 271, 273, 278–281
- homo- and hetero-associations of membrane proteins, *see* association patterns
- hop diffusion of membrane components 123–140
- HTLV-1 (human T-cell lymphotropic virus I) 98, 102, 111, 112, 113
- I**
- ICAM-1
- colocalization with MHC glycoproteins 80, 81
 - homo-association of 80, 81
- IL-15, *see* interleukin-15
- IL-15R, *see* interleukin-15 receptor
- IL-2, *see* interleukin-2
- IL-2/IL-15 signaling
- FKBP12.6 pathway 109, 110
 - JAK/STAT activation 97–104, 110, 112, 113
 - MAPK, *see* mitogen-activated protein kinase
 - mitogen-activated protein kinase (MAPK) pathway 110
 - NFAT, *see* nuclear factor of activated T cells
 - nuclear factor of activated T cells (NFAT) 107, 108, 110
 - phosphoinositide-3 kinase (PI-3K) pathway 109
 - PI-3K, *see* phosphoinositide-3 kinase
- IL-2/IL-15R beta subunit (IL-2Rβ) 8, 10, 11, 79, 81, 97–113
- IL-2/IL-15R system
- association with lipid rafts 82
 - association with MHC glycoproteins 79, 82, 83, 88, 89, 90
 - heterotetrameric model of 81, 105
- IL-2R, *see* interleukin-2 receptor
- immunological synapse (IS) 78, 81, 106, 164, 301, 302
- immunoreceptor tyrosine-based activation motif (ITAM) 211, 237, 238, 240, 243
- in B cell receptors 221, 230, 239
 - in Fc receptors 212, 213, 217, 219, 228, 229, 230, 239
 - in T cell receptors 14, 230

- immunoreceptor tyrosine-based inhibitory motif (ITIM) 14, 230, 237
- in FcεRI signaling cascade 227, 231, 233, 237–246
- interleukin-15 (IL-15) 1, 7–12, 18, 19, 81, 97–113
- transpresentation 106
- interleukin-15 receptor (IL-15R) 8, 10, 11, 79, 81, 82, 83, 88, 89, 90, 97–113
- alpha subunit (IL-15Rα) 8, 10, 11, 79, 81, 82, 83, 88, 89, 97–113
 - in immunotherapy 112
 - in mast cells 99, 101, 103,
- interleukin-2 (IL-2) 3, 7, 10, 16, 18, 81, 82, 97–113, 187, 191, 193, 216, 225, 227, 273, 293, 294, 295, 299, 306
- interleukin-2 receptor (IL-2R) 3, 16, 18, 82, 90, 97–113, 193
- alpha subunit (IL-2Rα, CD25) 77, 79, 81, 82, 88, 89, 97–113, 193
 - in immunotherapy 111
- ion channels 72, 266, 270, 293–307
- in apoptosis of T cells 305–307
 - in T cell activation 293–302
 - in volume regulation 302–305
 - intracellular 307
- IS, *see* immunological synapse
- ITAM, *see* immunoreceptor tyrosine-based activation motif
- ITIM, *see* immunoreceptor tyrosine-based inhibitory motif

J

- JAK/STAT activation
- in chemokine signaling 155, 161, 162
 - in IL-2/IL-15 signaling 97–104, 110, 112, 113

K

- K⁺ channels, *see* potassium channels

L

- laser scanning cytometry (LSC) 34
- lipid rafts, *see* also microdomains 58, 62, 72, 80, 81, 82, 88, 105, 126, 131, 132, 137, 145
- in chemokine signaling 164
 - in FcεRI stimulus-response coupling 213, 215–216, 219, 227, 236
 - in the IL-2/IL-15R system 82, 105
 - in TNFR signaling 185–186, 190
- LMP-1 (of Epstein-Barr virus) 176, 191
- LT, *see* lymphotoxin
- lymphotoxin (LT) 171, 175, 176, 177, 194
- ~β-receptor (LTβR) 173, 184, 191, 194

M

- magnetic beads 58–59
- major histocompatibility complex (MHC) 12, 13, 187, 241, 243, 293

- mast cells 99, 101, 103, 265, 268, 279, 280, 281
 – FcεRI signaling 213–245
 membrane potential 73, 179, 270, 293–307
 membrane skeleton 72, 125, 127–140, 146
 – f-actin-based 128
 – spectrin-based 128
 membrane-skeleton fence model 125,
 127–140, 146
 MHC I, *see* MHC-class I
 MHC II, *see* MHC-class II
 MHC, *see* major histocompatibility complex
 MHC-class I (MHC I) 1, 9, 11–19, 77, 102,
 105,
 – cis-interactions, *see* homo- and hetero-asso-
 ciations
 – free heavy chains, *see* misfolded heavy chain
 – homo- and hetero-associations of 14–19,
 77–81, 82, 90
 – misfolded heavy chain 16–19, 78,
 – oligomerization, *see* homo- and hetero-asso-
 ciations
 MHC-class II (MHC II)
 – homo- and hetero-associations of 80–83, 90
 Mik-beta1 monoclonal antibody 104, 112
 multichain immune recognition receptors
 (MIRR) 211, 225, 232, 234, 235, 246
 multiphoton microscopy 47, 48,
- N**
- natural killer (NK) cells 4, 7, 8, 10, 12, 18, 79,
 97, 98, 99, 100, 101, 102, 105, 106, 111, 112, 192,
 240, 241, 243, 244, 245,
 nervous system 173, 265, 270
 – histamine signaling 274–277
 NK, *see* natural killer
- O**
- oligomerization-induced trapping 126, 130,
 132, 138–139, 140, 146–147
 OPG, *see* osteoprotegerin
 osteoprotegerin (OPG) 173, 192, 195, 197
- P**
- p56^{lck} tyrosine kinase
 – in apoptosis 305, 306
 – in T cell activation 302
 – in volume regulation 304
 PLAD, *see* pre-ligand assembly domain
 plasma membrane compartmentalization 71,
 123–138
 potassium (K⁺) channels
 – blockers of 299–300
 – calcium (Ca²⁺)-activated 270, 295, 297–299,
 300
 – in apoptosis 305, 306
 – in T cell activation 294, 299–302
 – in volume regulation 303, 304
 – Kv, *see* voltage-gated
 – membrane distribution of 81, 300–302
 – voltage-gated (Kv) 72, 81, 295, 297–299, 300,
 301, 302, 303, 304, 305, 306
 pre-ligand assembly domain (PLAD) 177,
 196
 programmed cell death, *see* apoptosis
 protein clusters, *see also* association patterns
 of membrane proteins 56–59, 72, 77, 78,
 127, 142
 – hierarchical levels of 72, 78, 80
 – large (micrometer)-scale 57–58, 72, 78, 80
 – small (nanometer)-scale 56–57, 71, 78, 80
 protein patterns, *see* association patterns of
 membrane proteins
- Q**
- quantum dots (QD) 43–45, 46, 61
 QD, *see* quantum dots
- R**
- RBC, *see* red blood cells
 red blood cells (RBC) 1–8, 12, 19, 128
 – ~derived vesicles 6–7, 18
- S**
- scanning near field optical microscopy (SNOM)
 49, 57, 58, 59, 78,
 serotonin 161, 235, 243, 244, 270, 277
 single fluorescent molecule video imaging
 (SFVI) 123, 127, 129, 133
 single particle tracking (SPT) 80, 123, 127,
 128, 129, 130, 133, 134
 single-molecule imaging 123–148
 – detection of Ras activation 126, 140–148
 – in living cells 123, 126, 142–148
 – total internal reflection fluorescence micro-
 scope (TIRFM) 142, 143
 SFVI, *see* single fluorescent molecule video
 imaging
 SNOM, *see* scanning near-field optical
 microscopy
 SPT, *see* single particle tracking
 STED microscopy, *see* stimulated emission
 depletion microscopy
 stimulated emission depletion (STED)
 microscopy 48
 survival
 – coupled with TNFR signaling 171, 175, 177,
 180–189, 195
 – of T cells 1–19, 97, 101, 102, 109, 112, 113,
 187, 189
- T**
- T cells 78, 81, 231, 232, 234, 240, 241, 243, 245
 – activation of 3, 5, 11–12, 14, 16, 17, 19, 78,
 107, 108, 111, 173, 187, 191, 293–307

- calcium signaling 293–307
- interaction with APC 14, 17, 78, 81, 164, 187, 190, 293
- CD4+ 8, 18, 81, 101, 102, 105, 187, 193, 194, 273, 280
- CD8+ 3, 6, 7–12, 14, 18, 19, 97, 99, 101, 102, 106, 108, 112, 187, 190, 193, 245, 273, 280
- differentiation of 1, 7–12, 14, 15, 16, 18, 19
- growth of 1–20, 101
- lymphoma 79, 80, 81, 82, 88, 89, 104, 105, 113, 188
- regulation by chemokines 153, 154, 162, 164
- regulation by histamine 273, 279, 280, 281
- regulation by IL-2 and IL-15 97–113
- TNF/TNFR signaling 173, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198
- survival of 1–20, 97, 101, 102, 109, 112, 113, 187, 189
- T lymphocytes, *see* T cells
- TLR, *see* Toll-like receptor
- TNF, *see* tumor necrosis factor
- TNFR, *see* tumor necrosis factor receptor
- TNFR signaling
 - MAPK, *see* mitogen-activated protein kinase
 - mitogen-activated protein kinase (MAPK) pathway 175, 180, 181, 182, 184, 185, 186, 187, 191, 193, 197,
 - NF-kappaB, NF-κB, *see* nuclear factor kappaB
 - nuclear factor kappaB (NF-kappaB, NF-κB) pathway 175, 179, 180, 181, 182, 183–184, 187, 188, 189, 190, 191, 192, 193, 194, 195
- Toll-like receptor (TLR) 106, 181, 182
- transferrin receptor 79, 88, 89, 124, 129, 130, 132
- tumor necrosis factor (TNF) 3, 8, 107, 112, 154, 171–198, 212, 216, 222, 223, 224, 225, 227, 230, 233, 234, 239, 240, 246, 279
 - ~homology domain 173, 177
 - reverse signaling by 196–198
 - superfamily 171, 172, 173, 175, 177, 188, 196, 198

- tumor necrosis factor receptor (TNFR) 171–198
 - superfamily 171–173, 175, 177, 181, 182, 186, 196
- two-dimensional continuum fluid model, *see also* fluid mosaic membrane model 123, 124, 125, 126, 127, 130, 132, 133, 138, 140
- type I Fcε receptor (FcεRI) 211–246
 - expression of 212
 - structure of 211–212

V

- VFPs, *see* visible fluorescent proteins
- visible fluorescent proteins (VFPs) 36–42, 44
 - blue fluorescent protein (BFP) 36, 41
 - cyan fluorescent protein (CFP) 36, 40, 41, 42, 156, 157, 159
 - dimerization or oligomerization of 36, 40,
 - DsRed 36, 40
 - enhanced GFP (EGFP) 36,
 - green fluorescent protein (GFP) 34, 36, 37, 41, 42, 55, 56, 58, 59, 138, 145, 146, 148, 156
 - in FRET applications 41–42, 55–56, 141–144, 147, 156–157, 159
 - kindling fluorescent protein (KFPI) 40
 - photoactivation of GFP 40, 41
 - photophysical properties of 37–39
 - yellow fluorescent protein (YFP) 36, 37, 40, 41, 42, 141, 142, 143, 144, 145, 147, 156, 157, 159
- volume regulation
 - chloride (Cl⁻) channels 303, 304
 - Cl⁻ channels, *see* chloride channels
 - K⁺ channels, *see* potassium channels
 - of lymphocytes 302–305
 - potassium (K⁺) channels 303, 304
 - regulatory volume decrease (RVD) 293, 302–304
 - RVD, *see* regulatory volume decrease